SLAMF7

Across TCGA pan-cancer cohorts, SLAMF7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLAMF7 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SLAMF7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLAMF7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where SLAMF7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.400	0.923	.008	4	view →
HNSC	DFS	Tertile	II,III,IV	0.739	1.000	.028	3	view →
LUAD	OS	Tertile	III,IV	1.000	0.444	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLAMF7–LSCC (DFS)

Open the LSCC breakdown →